Tempus AI and the TIME100 Recognition
Tempus AI, Inc. (NASDAQ: TEM) has earned a spot on TIME’s prestigious list of the 10 Most Influential Health and Life Science Companies of 2026. The Chicago-based technology company advances precision medicine through the practical application of artificial intelligence. This recognition places Tempus among a select group of organizations transforming the future of global healthcare.
Eric Lefkofsky, Founder and CEO of Tempus AI, expressed what this honor means for the company. “This recognition from TIME speaks to our team’s focus on building a more connected and data-driven healthcare ecosystem,” he said. Furthermore, he noted that every patient should benefit from the data of those who came before them — a belief that has driven Tempus since its founding.
What Is the TIME100 Industry Leaders List?
A New Expansion of a Landmark Publication
The TIME100 Companies: Industry Leaders list is an inaugural expansion of the widely read TIME100 Most Influential Companies issue. TIME editors created this new format to dive deeper into 20 specific sectors. Each list highlights companies that shape their industries through extraordinary impact and measurable innovation. Therefore, inclusion on this list carries significant weight in the business and healthcare communities.
Why This Recognition Matters
Unlike general business rankings, the TIME100 Industry Leaders list evaluates companies on their real-world impact. Judges look at innovation, influence, and the ability to change how entire sectors operate. As a result, Tempus AI’s inclusion signals that its AI-driven approach is genuinely reshaping how healthcare is delivered and experienced.
Why Tempus AI Made the List
Bridging Data and Clinical Intelligence
TIME recognized Tempus specifically for its leadership in closing the gap between data and technology. The company makes genomic testing and clinical analysis more intelligent for patients. Traditionally, genomic data and clinical records existed in separate systems. Tempus built the infrastructure to connect them — enabling physicians to make more informed, data-backed decisions at the point of care.
A Mission Rooted in Personal Experience
Eric Lefkofsky launched Tempus after his wife received a breast cancer diagnosis. He noticed that very little data informed her treatment plan. Frustrated by this disconnect, he set out to apply technology and artificial intelligence directly to cancer care. Consequently, the company’s flagship xT test became one of the most clinically significant products in precision oncology.
The xT CDx Test: A Breakthrough in Tumor Profiling
How xT CDx Works
The xT CDx is Tempus’ FDA-approved, 648-gene tissue-based next-generation sequencing (NGS) test. It performs molecular profiling across all malignant solid tumors. Moreover, it combines genomic results with clinical data to help oncologists select targeted therapies and match patients to clinical trials. TIME specifically highlighted the xT CDx as a key reason for Tempus’ placement on the list.
Why This Matters for Patients
Before tools like xT CDx, oncologists relied heavily on limited genetic panels or broad chemotherapy regimens. Now, physicians can access a comprehensive genomic profile tied to clinical history. This approach leads to better-matched therapies, reduced trial-and-error treatment cycles, and improved patient outcomes. In short, the test represents a major step toward making precision medicine the standard of care.
Expanding Beyond Oncology
Cardiology, Radiology, and Neuropsychiatry
Tempus did not stop at cancer. The company has since expanded its AI-driven capabilities into cardiology, radiology, and neuropsychiatry. Each expansion brings the same data-connected intelligence that transformed oncology care into new clinical fields. Additionally, Tempus’ nP assay supports pharmacogenomic testing for patients with psychiatric conditions such as depression, bipolar disorder, and anxiety disorders.
Ambry Genetics Acquisition
Tempus strengthened its genetics portfolio through the acquisition of Ambry Genetics. This move brings hereditary cancer screening in-house. It also extends Tempus’ genetic testing capabilities into pediatrics, rare diseases, reproductive health, and inherited cardiac conditions. As a result, the company now offers a far broader spectrum of diagnostic services than ever before.
Strategic Partnerships Driving Innovation
Illumina Partnership
In 2025, Tempus entered a strategic partnership with Illumina, a global leader in genomics technology. Together, the two companies aim to standardize genomic profiling and molecular testing across all major diseases. This collaboration positions Tempus to drive consistency and scalability in genomic diagnostics at a global level.
AstraZeneca and Pathos AI Collaboration
Tempus has also partnered with AstraZeneca and Pathos AI to build the largest multimodal foundation model for oncology. This model aims to identify new cancer drug targets and accelerate therapeutic development. Consequently, these partnerships move Tempus beyond diagnostics and into the frontier of drug discovery and development.
A Vision for Data-Driven Healthcare
Tempus operates one of the world’s largest libraries of multimodal data. Its operating system makes that data accessible and useful for physicians across specialties. Looking ahead, Lefkofsky’s vision is clear: scale AI-driven insights across oncology, cardiology, neuropsychiatry, and beyond. Ultimately, Tempus is building a healthcare ecosystem where every patient benefits from the collective intelligence of those treated before them.
This TIME recognition affirms that the vision is working — and that Tempus AI stands at the forefront of the precision medicine revolution.
